Salts or co-crystals of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol

A salt or cocrystal of

• (a) (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol, and
• (b1) at least one acid selected from the group consisting of embonic acid, (2S,3S)-dibenzoyltartaric acid, sebacic acid, and 1-hydroxy-2-naphthoic acid, or
• (b2) at least one acid selected from the group consisting of nicotinic acid, hydrogen bromide, fumaric acid, and malonic acid
• wherein the salt or cocrystal of component (a) and component (b1) or the salt or cocrystal of component (a) and component (b2) is present in crystalline form, and
• wherein said crystalline form is selected from the group consisting of:
• a salt or cocrystal of embonic acid and (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol having at least one or more X-ray diffraction peaks selected from the group consisting of 7.94±0.20 (2θ), 10.40±0.20 (2θ), 14.25±0.20 (2θ), 17.18±0.20 (2θ) and 18.77±0.20 (2θ) or at least one or more X-ray diffraction peaks selected from the group consisting of 6.00±0.20 (2θ), 11.96±0.20 (2θ) and 17.61±0.20 (2θ);
• a hemi salt or cocrystal of (2S,3S)-dibenzoyltartaric acid and (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol having at least one or more X-ray diffraction peaks selected from the group consisting of 9.35±0.20 (2θ), 12.22±0.20 (2θ), 13.41±0.20 (2θ), 14.00±0.20 (2θ), 17.89±0.20 (2θ), 18.28±0.20 (2θ), 18.73±0.20 (2θ), 19.53±0.20 (2θ), 19.98±0.20 (2θ), 23.19±0.20 (2θ) and 24.33±0.20 (2θ);
• a salt or cocrystal of sebacic acid and (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol having at least one or more X-ray diffraction peaks selected from the group consisting of 12.16±0.20 (2θ), 15.31±0.20 (2θ), 16.88±0.20 (2θ), 18.90±0.20 (2θ), 22.66±0.20 (2θ), 23.08±0.20 (2θ) and 25.46±0.20 (2θ);
• a salt or cocrystal of 1-hydroxy-2-naphthoic acid and (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol having at least one or more X-ray diffraction peaks selected from the group consisting of 13.59±0.20 (2θ), 13.97±0.20 (2θ), 15.36±0.20 (2θ), 18.04±0.20 (2θ), 19.75±0.20 (2θ), 19.98±0.20 (2θ), 20.52±0.20 (2θ), 24.37±0.20 (2θ) and 26.09±0.20 (2θ);
• a salt or cocrystal of nicotinic acid and (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol having at least one or more X-ray diffraction peaks selected from the group consisting of 12.60±0.20 (2θ), 15.61±0.20 (2θ) and 22.82±0.20 (2θ) or at least one or more X-ray diffraction peaks selected from the group consisting of 10.34±0.20 (2θ), 12.14±0.20 (2θ), 22.38±0.20 (2θ), 23.65±0.20 (2θ) and 26.11±0.20 (2θ);
• a salt or cocrystal of hydrobromic acid and (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol having at least one or more X-ray diffraction peaks selected from the group consisting of 9.93±0.20 (2θ), 14.39±0.20 (2θ), 15.22±0.20 (2θ), 17.60±0.20 (2θ), 20.81±0.20 (2θ), 21.61±0.20 (2θ), 24.37±0.20 (2θ), 24.73±0.20 (2θ), 25.19±0.20 (2θ), 27.14±0.20 (2θ), 27.94±0.20 (2θ), 29.00±0.20 (2θ) and 30.75±0.20 (2θ);
• a salt or cocrystal of malonic acid and (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol having at least one or more X-ray diffraction peaks selected from the group consisting of 8.75±0.20 (2θ), 11.85±0.20 (2θ), 13.74±0.20 (2θ), 16.78±0.20 (2θ), 18.09±0.20 (2θ), 19.17±0.20 (2θ), 16.65±0.20 (2θ), 20.45±0.20 (2θ), 21.66±0.20 (2θ), 24.80±0.20 (2θ) and 25.55±0.20 (2θ);
• and
• a hemi salt or cocrystal of fumaric acid and (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol having at least one or more X-ray diffraction peaks selected from the group consisting of 11.86±0.20 (2θ), 15.26±0.20 (2θ), 16.00±0.20 (2θ), 16.21±0.20 (2θ), 17.52±0.20 (2θ), 21.75±0.20 (2θ), 22.35±0.20 (2θ), 24.57±0.20 (2θ) and 25.21±0.20 (2θ).